JSP191
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lower-risk Myelodysplastic Syndrome
Conditions
Lower-risk Myelodysplastic Syndrome
Trial Timeline
Jun 19, 2023 → Oct 21, 2024
NCT ID
NCT05903274About JSP191
JSP191 is a phase 1 stage product being developed by Jasper Therapeutics for Lower-risk Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT05903274. Target conditions include Lower-risk Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05903274 | Phase 1 | Terminated |
Competing Products
1 competing product in Lower-risk Myelodysplastic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion | Bristol Myers Squibb | Pre-clinical | 30 |